UNSPSC 51373422: Chlorpheniramine/codeine/glycerol, iodinated

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373422 Chlorpheniramine/codeine/glycerol, iodinated is a Commodity code that in practice captures state and local procurement of pharmaceutical products and over-the-counter health items, though the recent opportunities show limited direct alignment with the specific drug compound named in the code title. State and local issuing bodies soliciting under this code span county health departments and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary visible buyers. The work being solicited includes competitive procurement of naloxone and drug deactivation systems for community health support, and establishment of master agreements for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities. Vendors must meet standard compliance requirements including Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, FDA compliance, and established insurance thresholds.

Recent activity is concentrated in Florida and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors supplying MMCAP must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and accept a 3 percent administrative fee on all contract purchases with performance penalties of $200 to $1,500 per violation.